TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Weaning failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood cultures negative after 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Success rate of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mean duration of postoperative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in frequency of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal intensity of grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to evidence-based medicines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy lifestyle score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Severity of lens binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of brain tumor
Endpoint domain: Mortality/survival
Primary endpoint: Facial scores upon heel lance and recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and duration of crying in recovery period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight at 24 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea/vomiting as adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve (AUC0-12) of vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (C max) of vonoprazan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived value of training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peripheral leucocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nocturnal fall of mean BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FM DFA augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: successful ocular surface reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of motility restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of symblepharon
Endpoint domain: Adverse events/effects
Primary endpoint: Performance in the Groton Maze learning test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ventilation time in cardiac care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall performance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to target temperature of 34 degrees C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nutritional recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in ergonomic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in accuracy of self-assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure performance speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of recorded postprandial blood glucose levels < 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum 25(OH)D increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total serum calcium levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parathyroid hormone levels decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: basal prolactin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rates of preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: Cervical length changes over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: VO2 measured at five minutes into the TTE100%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T/E-2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of symptomatic uncomplicated diverticular disease (SUDD)
Endpoint domain: Mortality/survival
Primary endpoint: Mean bone mineral density in zone 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bone mineral density in zone 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment failure (cardiovascular death or rehospitalization for heart failure)
Endpoint domain: Mortality/survival
Primary endpoint: Pleural effusion
Endpoint domain: Adverse events/effects
Primary endpoint: Pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IBS-specific symptom score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: knee joint active motion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HSS knee joint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: self-function satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Push-off power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to complete sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Serum concentrations of MDA and vitamin E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: S‐metoprolol maximum concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: enjoyment and reward value of activities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in the number of blisters and erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Odds of at-risk drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Metastasis-Free Survival (BMFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to bone metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in plasma IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recession width (RW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: group cohesion
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: confidence in helping others
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Left atrial volume (LAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PDV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use in sexually active boys
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: recurrence of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weight loss greater than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate (> or =50% reduction in seizure frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in femoral intima-media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in frequency of femoral plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Risk of Myocardial Infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients reported to transportation administrators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Arterial Pressure (MAP) during sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpO2 scores during sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Significant pain relief (≥50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status improvement (≥50%)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neutrophil apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative number of coughs per dose of mannitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Protection for bronchoconstriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean charge to induce intra-operative MEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAR reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutrition behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to no advancement of cellulitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: SDLP (Standard Deviation of Lateral Position)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSA (Time to Steer Again)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death, MI or TLR
Endpoint domain: Mortality/survival
Primary endpoint: Rate of clinical pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return of serum calcium level to normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: misfires
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: OR time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early post-operative pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cats free of ticks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of cats free of fleas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Health utilities (SF-6D and EQ-5D scores)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subclinical hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median urinary iodine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of 25-hydroxyvitamin D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: parent-rated social responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in flour dust and allergen exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuro-ICU length of stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Exposure equivalence of intravenous and oral temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum IGF‐I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean plasma IGFBP‐3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Need for sedation during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Need for atropine and/or ephedrine during surgery
Endpoint domain: Adverse events/effects
Primary endpoint: late survival rate
Endpoint domain: Mortality/survival
Primary endpoint: assisted patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: repeat operations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensory and motor block level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Home discharge time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intention-to-treat PEP rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IVELT after 8 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOD, GSH‐Px, and MDA levels after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with no PONV within 24 hr of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for narcotic analgesia in the postanesthetic care unit
Endpoint domain: Adverse events/effects
Primary endpoint: Serum glucose levels in the postanesthetic care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of confirmed hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: mean requirement for propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐procedure satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall success of ultrasonographically guided needle aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success of incision and drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to maintain and rapidly shift mental set
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed memory recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined cumulative fractional LCSFA oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net LCSFA oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage dietary LCSFA contribution to total fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TP (Treatment Progress)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TM (Treatment Management)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF (Activity Functioning)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in functional disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores in the first 48h after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rate of pain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of pain after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of a soft/regular diet at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative analgesia (TAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NTP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Second-day blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of trial failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for patient sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menopausal symptoms relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of gastric H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: reflection impulsivity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: initial thinking times during planning improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adjustment difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fewer sensitizations towards aeroallergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severe hypertriglyceridaemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Effort required to stay on treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of maternal hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal outcome (umbilical arterial pH, Apgar score, NACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolactin response to d-fenfluramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: improvement in life changes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: reduction in unhealthy days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maternal heart rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac arrhythmia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for consultation audiotapes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean time to reach preoperative test performance +10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise-related hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Chronic lung disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mother-reported asthma/wheezing/croup diagnostics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: successful anterior vaginal wall support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Urogenital Distress Inventory-6 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire-12 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: immediate pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum PSA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement during scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful AVF access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AVF survival rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Rate of device-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety profile of Buprenorphine during pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: serious adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: infections (CMV infections)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of psychosis cluster scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain and metabolic abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: minute ventilation (Ve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: anxiety change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes